Top

01-09-2016 | Original Research

Radiographic changes in lung of patients treated with stereotactic ablative body radiation therapy: low-dose volumes as the driving force for radiographic change

Published in: Journal of Radiation Oncology | Issue 3/2016

Abstract

Objective

To describe radiographic evidence of radiation pneumonitis (rRP) and fibrosis (rRF) and determine what dosimetric parameters correlate with rRP and rRF after stereotactic ablative radiation therapy (SABR) to the lung.

Methods

Ninety-eight follow-up computed tomography (CT) scans from 32 patients treated by SABR were retrospectively reviewed for CT appearance of rRP and rRF determined by the Ikezoe (≤6 months) and Koenig (≥7 months) systems. The dosimetric correlations for rRP, rRF, and fibrotic volume were analyzed.

Results

There was a 55 % incidence of rRP and 59 % incidence of rRF with a median follow-up of 10 months. Only the low-dose parameters V _2.5, V ₅, V ₇, and V ₁₀ (the volume of lung receiving more than 2.5, 5, 7, and 10 Gy of radiation, respectively) were correlated to the development of rRP (p < 0.05). No parameter correlated with rRF, but V ₅, V ₇, and V ₁₀ trended toward significance. The absolute fibrotic volume was correlated with the planning target volume (p = 0.01) and V ₇ (p = 0.02).

Conclusion

The development of rRP and the fibrotic volume after SABR was correlated with the volume of lung that received lower doses of radiation.

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O’Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC (2010) Non-small cell lung cancer. J Natl Comp Cancer Network: JNCCN 8(7):740–801

Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682. doi:10.1016/j.ijrobp.2008.11.042 CrossRefPubMed

Linda A, Trovo M, Bradley JD (2011) Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol 79(1):147–154. doi:10.1016/j.ejrad.2009.10.029 CrossRefPubMed

Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J (2010) Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 69(1):77–85. doi:10.1016/j.lungcan.2009.09.006 CrossRefPubMed

Ikezoe J, Takashima S, Morimoto S, Kadowaki K, Takeuchi N, Yamamoto T, Nakanishi K, Isaza M, Arisawa J, Ikeda H, et al. (1988) CT appearance of acute radiation-induced injury in the lung. AJR Am J Roentgenol 150(4):765–770CrossRefPubMed

Koenig TR, Munden RF, Erasmus JJ, Sabloff BS, Gladish GW, Komaki R, Stevens CW (2002) Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol 178(6):1383–1388CrossRefPubMed

Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M (2007) Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 85(3):435–442. doi:10.1016/j.radonc.2007.10.044 CrossRefPubMed

Bradley J (2007) Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2(7 Suppl 3):S118–S124. doi:10.1097/JTO.0b013e318074e50c CrossRefPubMed

Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S (2011) Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 6(7):1221–1228. doi:10.1097/JTO.0b013e318219aac5 CrossRefPubMed

10.

Kyas I, Hof H, Debus J, Schlegel W, Karger CP (2007) Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 67(3):768–774. doi:10.1016/j.ijrobp.2006.08.066 CrossRefPubMed

11.

Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G, Flentje M (2010) Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 97(1):65–70. doi:10.1016/j.radonc.2010.04.027 CrossRefPubMed

12.

Palma DA, van Sornsen de Koste J, Verbakel WF, Vincent A, Senan S (2010) Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010.07.025

13.

Prendergast BM, Bonner JA, Popple RA, Spencer SA, Fiveash JB, Keene KS, Cerfolio RJ, Minnich DJ, Dobelbower MC (2011) Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapy. J Med Imaging Radiat Oncol 55(1):90–96. doi:10.1111/j.1754-9485.2010.02234.x CrossRefPubMed

14.

Aoki T, Nagata Y, Negoro Y, Takayama K, Mizowaki T, Kokubo M, Oya N, Mitsumori M, Hiraoka M (2004) Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology 230(1):101–108. doi:10.1148/radiol.2301021226 CrossRefPubMed

15.

Vinogradskiy Y, Diot Q, Kavanagh B, Schefter T, Gaspar L, Miften M (2013) Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys 40(8):081712. doi:10.1118/1.4813916 CrossRefPubMed

16.

Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ, Schilstra C, Henning GT, Hayman JA, Martel MK, Ten Haken RK (2003) Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 55(3):724–735CrossRefPubMed

17.

Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC (2005) Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63(3):672–682. doi:10.1016/j.ijrobp.2005.03.026 CrossRefPubMed

18.

Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B (2005) Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61(2):318–328. doi:10.1016/j.ijrobp.2004.06.260 CrossRefPubMed

19.

Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M (2012) Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int J Radiat Oncol Biol Phys 84(4):1024–1030. doi:10.1016/j.ijrobp.2011.11.080 CrossRefPubMed

20.

Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y, Wadasaki K, Hirokawa Y, Ito K, Okawa M (2006) CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 66(2):483–491. doi:10.1016/j.ijrobp.2006.05.008 CrossRefPubMed

21.

Ghobadi G, Hogeweg LE, Faber H, Tukker WG, Schippers JM, Brandenburg S, Langendijk JA, Coppes RP, van Luijk P (2010) Quantifying local radiation-induced lung damage from computed tomography. Int J Radiat Oncol Biol Phys 76(2):548–556. doi:10.1016/j.ijrobp.2009.08.058 CrossRefPubMed

22.

Chi A, Wen S, Liao Z, Fowler J, Xu J, Nguyen NP, Welsh JS, Komaki R (2013) What would be the most appropriate alpha/beta ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. BioMed Res Int 2013:391021. doi:10.1155/2013/391021 PubMedPubMedCentral

23.

Guckenberger M, Klement RJ, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M (2013) Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol 109(1):13–20. doi:10.1016/j.radonc.2013.09.005 CrossRefPubMed

24.

Casamassima F, Masi L, Bonucci I, Polli C, Menichelli C, Gulisano M, Pacini S, Aterini S, Cavedon C (2008) Relevance of biologically equivalent dose values in outcome evaluation of stereotactic radiotherapy for lung nodules. Int J Radiat Oncol Biol Phys 71(1):145–151. doi:10.1016/j.ijrobp.2007.09.036 CrossRefPubMed

25.

Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25(8):947–952. doi:10.1200/jco.2006.09.7469 CrossRefPubMed

26.

Hof H, Zgoda J, Nill S, Hoess A, Kopp-Schneider A, Herfarth K, Debus J, Plathow C (2010) Time- and dose-dependency of radiographic normal tissue changes of the lung after stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77(5):1369–1374. doi:10.1016/j.ijrobp.2009.06.082 CrossRefPubMed

27.

Komaki R, Travis E, Cox J (2010) The lung, pleura, and thymus. In: Cox J, Ang K (eds) Radiation oncology: rationale, technique. Results. Ninth edn. Mosby, Inc., Philadelphia, PA, p. 425

28.

Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33(1):99–109CrossRefPubMed

29.

Senthi S, Dahele M, van de Ven PM, Slotman BJ, Senan S (2013) Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques. Radiother Oncol 109(1):77–81. doi:10.1016/j.radonc.2013.08.034 CrossRefPubMed

30.

Yang M, Zhang L, Bi N, Ji W, Tan W, Zhao L, Yu D, Wu C, Wang L, Lin D (2011) Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 79(5):1402–1407. doi:10.1016/j.ijrobp.2009.12.042 CrossRefPubMed

31.

Xiong H, Liao Z, Liu Z, Xu T, Wang Q, Liu H, Komaki R, Gomez D, Wang LE, Wei Q (2013) ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 85(4):1066–1073. doi:10.1016/j.ijrobp.2012.09.024 CrossRefPubMed

Title: Radiographic changes in lung of patients treated with stereotactic ablative body radiation therapy: low-dose volumes as the driving force for radiographic change
Publication date: 01-09-2016
Published in: Journal of Radiation Oncology / Issue 3/2016
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-016-0254-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine